Skip to main content

Table 3 The incidence rates of treatment-related adverse events

From: Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex

EventImproved group
(n = 23)
Unchanged group
(n = 10)
Acne2 (9%)2 (20%)
Application site irritation2 (9%)1 (10%)
Dry skin3 (13%)0 (0%)
Pruritus1 (4%)1 (10%)